160 related articles for article (PubMed ID: 37875740)
21. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
22. Survival outcomes of epithelial ovarian cancer treated at a tertiary-level hospital in India.
Chandy RG; Thomas V; Sebastian A; Mani T; Thomas A; Joel A; Ram TS; Peedicayil A
Indian J Cancer; 2023 Oct; 60(4):475-485. PubMed ID: 38185864
[TBL] [Abstract][Full Text] [Related]
23. Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer.
Angeles MA; Spagnolo E; Cabarrou B; Pérez-Benavente A; Gil Moreno A; Guyon F; Rychlik A; Migliorelli F; Bataillon G; Navarro AS; Betrian S; Ferron G; Hernández A; Martinez A
Int J Gynecol Cancer; 2023 Jan; 33(1):50-56. PubMed ID: 36446410
[TBL] [Abstract][Full Text] [Related]
24. Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications.
de Jong D; Thangavelu A; Broadhead T; Chen I; Burke D; Hutson R; Johnson R; Kaufmann A; Lodge P; Nugent D; Quyn A; Theophilou G; Laios A
J Ovarian Res; 2023 Nov; 16(1):214. PubMed ID: 37951927
[TBL] [Abstract][Full Text] [Related]
25. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
Hiu S; Bryant A; Gajjar K; Kunonga PT; Naik R
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD007697. PubMed ID: 36041232
[TBL] [Abstract][Full Text] [Related]
26. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
27. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
Drews F; Bertelli G; Lutchman-Singh K
Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
Song N; Gao Y
Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
[TBL] [Abstract][Full Text] [Related]
29. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
[TBL] [Abstract][Full Text] [Related]
30. Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival.
Rajkumar S; Nath R; Lane G; Mehra G; Begum S; Sayasneh A
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():26-31. PubMed ID: 30639953
[TBL] [Abstract][Full Text] [Related]
31. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
[TBL] [Abstract][Full Text] [Related]
32. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer.
Greer A; Gockley A; Manning-Geist B; Melamed A; Sisodia RC; Berkowitz R; Horowitz N; Del Carmen M; Growdon WB; Worley M
Int J Gynecol Cancer; 2021 Oct; 31(10):1341-1347. PubMed ID: 34429355
[TBL] [Abstract][Full Text] [Related]
33. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
34. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
35. Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.
Matsuo K; Tanabe K; Ikeda M; Shibata T; Kajiwara H; Miyazawa M; Miyazawa M; Hayashi M; Shida M; Hirasawa T; Roman LD; Mikami M
Arch Gynecol Obstet; 2018 Mar; 297(3):749-756. PubMed ID: 29340789
[TBL] [Abstract][Full Text] [Related]
36. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
37. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer.
Bogani G; Leone Roberti Maggiore U; Paolini B; Diito A; Martinelli F; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2019 Jan; 30(1):e4. PubMed ID: 30479088
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
[TBL] [Abstract][Full Text] [Related]
39. A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer.
Liberale G; Pop CF; Polastro L; Kerger J; Moreau M; Chintinne M; Larsimont D; Nogaret JM; Veys I
J Visc Surg; 2020 Apr; 157(2):79-86. PubMed ID: 31837942
[TBL] [Abstract][Full Text] [Related]
40. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
